GIANT Protocol Raises $5 Million Seed Round Led by CoinFund
16.12.2021 19:30:00 EET | Business Wire | Press release
GIANT Protocol, a leading-edge web3 protocol to decentralize and democratize access to the internet and financial services, is delighted to announce it has raised USD $5 million in a seed funding round led by pioneer blockchain-focused investment firm, CoinFund, with additional participation from other tier one blockchain investors including Blockchange, Gumi Cryptos, Entheos Ventures, Argonautic Ventures, Bronco Fund. The round was oversubscribed.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211216005703/en/
GIANT Protocol Team: Left to Right: Merijn Terheggen COO and Co Founder (left), Suruchi Gupta CEO and Founder (center), Jinesh Doshi, Founding Engineer (right) (Photo: Business Wire)
GIANT (Global Internet Access Network Token) Protocol was founded with the objective to launch a decentralized connectivity economy that can address multiple challenges in the telecom industry. The tokenized bandwidth platform will enable anyone with a mobile phone to access the internet and earn rewards based on their connectivity. GIANT Protocol is in an advanced stage of development with an experienced founding team and a well-established network in the telecom sector.
Suruchi Gupta, Co-Founder and CEO of GIANT, commented "At GIANT, we believe internet access is a basic human right and that an Internet that works for everyone can only be built together. We are at the start of our journey, but we are honoured to have received support from tier one investors who fundamentally understand the problem we are solving with GIANT.”
Jake Brukhman, Founder and CEO CoinFund, said “Telco networks have historically been functionally local, yet our lives have become more international and interconnected. Customers are looking for better telecom services experience all over the World. GIANT is moving the world forward by establishing a new global connectivity economy.”
He added: “As a strategic fund, CoinFund is passionate about being the best partner to early-stage blockchain companies. Suruchi is a rising star in the world of technology and she is also working with some of the most seasoned and respected technology leaders in the industry to bring this idea into a practical utility the world over. GIANT has uniquely pledged to convert bandwidth into a digital asset that can be used as a currency and we are pleased to support this innovative team as they continue to develop their Global Internet Access Network Token.”
As part of GIANT’s development, the project has also hired a world-class team of executives hailing from Juniper, Salesforce, HackerOne, Roku, Mobile365, and others. The team has collectively raised $200M+ in the past and has generated $10B+ in value.
Merijn Terheggen, Co-Founder and COO, has extensive experience at building startups. Before joining GIANT as a Co-Founder, Merijn Terheggen cofounded HackerOne and served as its CEO. HackerOne is the leading and still rapidly growing bug bounty platform that has raised $110M in funding, has about 350 employees, and has 2 million hackers that have found and reported hundreds of thousands of serious security vulnerabilities in thousands of large companies, governments, and banks.
Merijn Terheggen, commented: “HackerOne was created from a desire to unite people working on security and unlock the creativity and ingenuity of those trying to get around obstacles. The key for us had always been about community and collaboration, and rewarding creativity and merits. GIANT is taking this philosophy to a whole new level by leveraging blockchain. Where HackerOne aims to empower the world to build a safer internet, GIANT expands this mission by aiming to empower the world to build the digital infrastructure that humanity will need in the coming decades. And of course this infrastructure is decentralized, democratized, accessible to anyone, and owned by everyone. It is an honour to work with Suruchi and the team on this mission.”
ENDS
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005703/en/
Contact information
Rachel McHugh
Rachel@cw8-communications.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FPT Named an OpenAI Select Partner6.8.2026 03:00:00 EEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 01:10:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of ORZEYFUL marks a new chapter for the narcolepsy type 1 community, as we introduce an entirely new class of medicine that will potentially redefine how this disease is managed and howpeople feel on treatment,” said Julie Kim, president and chief executive officer of Takeda. “We are proud to have discovered and developed this orexin treatment innovation and will bring it to adults living with NT1 as quickly as possible.” NT1 is a rare, chronic neurological disease d
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 23:30:00 EEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 17:05:00 EEST | Press release
Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership, and operational excellence with a track record of execution from first-in-human studies through regulatory
Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 17:00:00 EEST | Press release
Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom